Rossari Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Rossari Biotech şirketinin toplam hissedar öz sermayesi ₹11.2B ve toplam borcu ₹1.4B olup, bu da borç-öz sermaye oranını 12.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹17.1B ve ₹5.9B dir. Rossari Biotech 'in FAVÖK'ü ₹1.9B faiz karşılama oranı 14.5 dur. Şirketin ₹800.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

12.8%

Borç/özkaynak oranı

₹1.43b

Borç

Faiz karşılama oranı	14.5x
Nakit	₹800.08m
Eşitlik	₹11.18b
Toplam yükümlülükler	₹5.93b
Toplam varlıklar	₹17.11b

Son finansal sağlık güncellemeleri

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Jun 14

Recent updates

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Aug 17

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Jun 14

Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals

May 07

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

May 03

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Feb 10

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

Sep 23

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Apr 06

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Feb 19

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Feb 17

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Feb 10

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Nov 24

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Oct 12

Is Rossari Biotech Limited's (NSE:ROSSARI) Latest Stock Performance Being Led By Its Strong Fundamentals?

Dec 17

Rossari Biotech (NSE:ROSSARI) Is Growing Earnings But Are They A Good Guide?

Oct 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ROSSARI 'nin kısa vadeli varlıkları ( ₹9.4B ) kısa vadeli yükümlülüklerini ( ₹4.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: ROSSARI şirketinin kısa vadeli varlıkları ( ₹9.4B ) uzun vadeli yükümlülüklerini ( ₹1.4B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ROSSARI 'nin net borç/öz sermaye oranı ( 5.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: ROSSARI 'nin borç/öz sermaye oranı son 5 yılda 17.4% seviyesinden 12.8% seviyesine düştü.

Borç Kapsamı: ROSSARI 'nin borcu işletme nakit akışı ( 81.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: ROSSARI 'in borcuna ilişkin faiz ödemeleri EBIT ( 14.5 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Rossari Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Recent updates

Now 22% undervalued after recent price drop

Rossari Biotech Limited Appoints Gurudas Aras as an Additional Director Designated as Non- Executive Independent Director

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited to Report Q2, 2025 Results on Oct 19, 2024

Price target increased by 7.6% to ₹951

Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March, 2024

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Upcoming dividend of ₹0.50 per share

Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Rossari Biotech Limited to Report Q1, 2025 Results on Jul 20, 2024

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

Full year 2024 earnings: EPS misses analyst expectations

Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024

Now 20% undervalued

Price target increased by 9.0% to ₹852

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Price target decreased by 8.4% to ₹782

Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)

Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023

First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)

Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Investor sentiment improves as stock rises 16%

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Upcoming dividend of ₹0.50 per share at 0.1% yield

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Consensus revenue estimates fall by 13%

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Price target decreased by 9.2% to ₹986

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent Director

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)

Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)

Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022

Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Upcoming dividend of ₹0.50 per share

Full year 2022 earnings: EPS misses analyst expectations

Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022

Price target decreased to ₹1,252

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to ₹1,330

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Insider recently sold ₹2.1m worth of stock

Price target increased to ₹1,270

First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)

Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals Business

Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.

Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)

Investor sentiment improved over the past week

Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investors

Investor sentiment improved over the past week

New 90-day high: ₹991

Third quarter 2021 earnings released: EPS ₹4.16

Rossari Biotech Limited to Report Q3, 2021 Results on Jan 23, 2021

Investor sentiment improved over the past week